NewAmsterdam Pharma Company N.V. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
NewAmsterdam Pharma Company N.V. (NAMS) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$5.14 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-05
- NewAmsterdam Pharma Company N.V. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $5.18M, a 260.32% increase year-over-year.
- NewAmsterdam Pharma Company N.V. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$10.33M.
- NewAmsterdam Pharma Company N.V. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $5.32M, a 122.39% increase year-over-year.
- NewAmsterdam Pharma Company N.V. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $638.00K, a 58.71% increase year-over-year.
- NewAmsterdam Pharma Company N.V. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $2.45M, a 45.20% increase from fiscal 2024.
- NewAmsterdam Pharma Company N.V. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $1.69M, a 69.18% decline from fiscal 2023.
- NewAmsterdam Pharma Company N.V. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $5.47M.
- NewAmsterdam Pharma Company N.V. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was -$8.68M, a 376.05% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$5.14M 10-Q · filed 2026-08-05 | $179.00K derived: sum of 3 quarters · filed 2026-08-05 | $817.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$10.33M 10-Q · filed 2026-05-07 | -$5.01M derived: sum of 2 quarters · filed 2026-05-07 | -$4.37M derived: sum of 3 quarters · filed 2026-05-07 | -$2.93M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $5.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $5.96M derived: sum of 2 quarters · filed 2026-02-18 | $7.40M derived: sum of 3 quarters · filed 2026-08-05 | $2.45M 10-K · filed 2026-02-18 |
| 2025-09-30 | $638.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.08M derived: sum of 2 quarters · filed 2026-08-05 | -$2.88M 10-Q · filed 2025-11-05 | -$482.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$3.51M 10-Q · filed 2026-08-05 | -$1.12M derived: sum of 3 quarters · filed 2026-08-05 | -$718.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$4.95M 10-Q · filed 2026-05-07 | -$2.56M derived: sum of 2 quarters · filed 2026-05-07 | -$2.16M derived: sum of 3 quarters · filed 2026-05-07 | -$1.89M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $2.80M derived: sum of 2 quarters · filed 2026-02-18 | $3.07M derived: sum of 3 quarters · filed 2026-02-18 | $1.69M 10-K · filed 2026-02-18 |
| 2024-09-30 | $402.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $673.00K derived: sum of 2 quarters · filed 2025-11-05 | -$708.00K 10-Q · filed 2025-11-05 | -$6.50M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-06-30 | $271.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$1.11M 10-Q · filed 2025-08-06 | -$6.91M derived: sum of 3 quarters · filed 2026-02-18 | $2.44M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-03-31 | -$1.38M 10-Q · filed 2025-05-08 | -$7.18M derived: sum of 2 quarters · filed 2026-02-18 | $2.16M derived: sum of 3 quarters · filed 2026-02-18 | -$2.91M derived: sum of 4 quarters · filed 2026-02-18 |
| 2023-12-31 | -$5.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $3.54M derived: sum of 2 quarters · filed 2026-02-18 | -$1.53M derived: sum of 3 quarters · filed 2026-02-18 | $5.47M 10-K · filed 2026-02-18 |
| 2023-09-30 | $9.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $4.27M derived: sum of 2 quarters · filed 2024-11-06 | $11.27M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$5.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $1.93M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $7.00M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | -$8.68M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $3.14M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |